Department of Pathology, Duke University and Durham Veterans Affairs Medical Centers, Durham, NC, USA.
Division of Hematology/Oncology, Department of Medicine, The University of North Carolina Medical Center, Chapel Hill, NC, USA.
J Thromb Haemost. 2016 Jun;14(6):1249-54. doi: 10.1111/jth.13311. Epub 2016 Apr 5.
Essentials Disorders of hemostasis can lead to delayed and defective wound healing. In hemophilia B (HB) mice, 7 days of Factor (F)IX or VIIa are needed to normalize wound healing. One dose of a highly active FVIIa variant (DVQ) restored normal wound closure time in HB mice. Coagulation factors with enhanced activity may acquire biological effects not due to hemostasis.
Introduction We have previously reported that hemophilia B (HB) mice have delayed healing of cutaneous wounds and alterations in wound histology. Administration of a single dose of either factor IX or recombinant activated FVII (rFVIIa) (NovoSeven) prior to wounding did not improve wound closure time or histology. The FVIIa analog DVQ (V158D, E296V and M298Q mutations) was designed to have higher tissue factor-independent activity than rVIIa. We hypothesized that a single dose of DVQ would be more effective in restoring wound healing in HB mice. Methods Cutaneous punch wounds were made on the backs of HB and wild-type mice, and the time to wound closure was monitored. HB mice were treated with a dose of rFVIIa (10 mg kg(-1) ) or DVQ (1 mg kg(-1) ) that corrected the tail bleeding time. Skin samples were taken at various time points after wounding, fixed, and stained, and the histology was examined. Results As previously reported, wound closure times in HB mice given one dose of rFVIIa were not improved over those in untreated HB mice. Surprisingly, healing times in HB mice treated with an equally hemostatic dose of DVQ were normalized to that in wild-type mice. However, DVQ did not correct all histologic abnormalities in HB mice. Conclusions As the doses of DVQ and rFVIIa were chosen to support comparable levels of hemostasis, our data suggest that the improved healing seen with DVQ is not solely attributable to its hemostatic activity. It is possible that the improved wound healing arises through the effect of DVQ on cell signaling mechanisms.
止血功能紊乱可导致伤口愈合延迟和不充分。在乙型血友病(HB)小鼠中,需要给予因子(F)IX 或 VIIa7 天才能使伤口愈合正常化。一剂高活性的 VIIa 变体(DVQ)可使 HB 小鼠的正常伤口闭合时间恢复正常。具有增强活性的凝血因子可能获得与其止血作用无关的生物学效应。
我们之前报道过,HB 小鼠的皮肤伤口愈合延迟,伤口组织学发生改变。在创伤前给予一剂因子 IX 或重组激活的 FVII(rFVIIa)(诺维金)均不能改善伤口闭合时间或组织学。FVIIa 类似物 DVQ(V158D、E296V 和 M298Q 突变)的设计目的是使其具有比 rVIIa 更高的组织因子非依赖性活性。我们假设一剂 DVQ 将更有效地恢复 HB 小鼠的伤口愈合。
在 HB 和野生型小鼠的背部制作皮肤打孔伤,并监测伤口闭合时间。HB 小鼠用纠正尾部出血时间的 rFVIIa(10mg/kg)或 DVQ(1mg/kg)剂量治疗。在创伤后不同时间点采集皮肤样本,固定并染色,检查组织学。
如前所述,接受一剂 rFVIIa 治疗的 HB 小鼠的伤口闭合时间并未优于未治疗的 HB 小鼠。令人惊讶的是,用与 rFVIIa 相当的止血剂量 DVQ 治疗的 HB 小鼠的愈合时间正常化至与野生型小鼠相同。然而,DVQ 并未纠正 HB 小鼠的所有组织学异常。
由于选择 DVQ 和 rFVIIa 的剂量以支持相当的止血作用,我们的数据表明,DVQ 改善的愈合不仅仅归因于其止血活性。有可能通过 DVQ 对细胞信号转导机制的影响来改善伤口愈合。